Navigation Links
Gemzar the New Drug for Recurrent Ovarian Cancer

The FDA has approved Gemzar for the treatment of recurrent ovarian cancer ignoring the advice of the FDA panel.//

It said that Gemzar in combination with carboplatin (chemotherapy) is very effective for women with advanced ovarian cancer. The drug Gemzar also known by its generic name gemcitabine and was approved after the company provided with additional information to the FDA. According to the statistics of the American Cancer Society about 22,000 women are diagnosed with the disease and 16,000 women die each year. The problem with ovarian cancer is that the tumor tends to recur, making the treatment difficult and resulting in low survival rates.

Gemzar is already approved in the US for lung, pancreatic and breast cancers. In the clinical trails it was found that ovarian cancer patients taking Gemzar with carboplatin had increased progression-free survival rates than patients taking carboplatin alone. The FDA advisory panel voted against recommending the drug when the panel members were concerned that patients in the trial did not survive longer than those taking carboplatin alone. But the company replied that their aim is to prevent the cancer from worsening and not to help patients live longer. The treatment with Gemzar costs about $12,600 which does not increase the longevity of the patient but allows them to have less frequent chemotherapy.


'"/>




Page: 1

Related medicine news :

1. Estrogen Does Not Prevent Recurrent Strokes
2. Radiation Therapy An Effective Solution For Recurrent Prostate Cancer
3. Prevention Of Recurrent Leg Ulcers
4. Measuring Urinary Protein Helps In Detecting Recurrent Bladder Cancer
5. Sertraline Can Prevent Recurrent Depressive Episodes In Diabetics
6. Angola Warned of Recurrent Cholera Outbreaks
7. Recurrent Stroke Risk is Minimized by Statin
8. Blood Markers Predict Risk for Recurrent Stroke and Mortality
9. Targeted Compound Helps Recurrent Prostate Cancer Patients
10. Ancient Indian Herb May Prove Cure For Recurrent UTI
11. Ovarian cancer in relationship with Hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gemzar the New Drug for Recurrent Ovarian Cancer

(Date:4/23/2014)... Va., April 23, 2014 The American Society for ... "The Role of Postoperative Radiation Therapy for Endometrial ... use of adjuvant radiation therapy in the treatment ... published in the May-June 2014 issue of ... practice journal of ASTRO. The full-length guideline is ...
(Date:4/23/2014)... researchers have developed a way to detect and measure ... gold particles with tails of synthetic DNA., A team ... engineering, used gold nanoparticles to target and bind to ... splice variants, which can indicate the presence and stage ... variants in a cell can be determined by examining ...
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
(Date:4/23/2014)... In science, "simple and accessible detection methods that ... the resolution of a single cell inside that ... chemical engineer Chang Lu. , In the Royal ... Lu has announced that he and his coworkers ... subcellular location of a protein ( Chem. Sci. ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... , SAN DIEGO, Dec. 2 US Farms, ... and Wellness products, is pleased to announce it will be ... Calif., at the Oakland Zoo on December 11-20, 2009. , ... at 877-90-FARMS or visit http://cookswareafaire.com , Victor Brandstetter, ...
... , American Red Cross also ... WASHINGTON, Dec. 2 The Hewlett-Packard Company Foundation has contributed ... Red Cross disaster response. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) ... Philippine communities affected by typhoons in September and October. Other ...
... , , NASHVILLE, Tenn., Dec. 2 ... development company, has appointed Pearson Talbert as chief development ... Talbert will provide leadership and vision to the sales ... help hospitals grow revenues through employer partnerships and physician ...
... , BELLEVUE, Wash., ... leading online retailer of health, beauty, vision and pharmacy products ... China, India, and Brazil, plus 50 additional countries worldwide. More ... beauty and wellness products on http://international.drugstore.com with pricing ...
... the gene could be linked to life span in males ... affect life span in humans and other mammals and could ... Japanese scientists say. , The researchers found that mice created ... average of 186 days longer than mice created from the ...
... not advised, expert says , WEDNESDAY, Dec. 2 (HealthDay ... their heart might be helping their eyes as well. ... what they described as a modest benefit for aspirin ... that destroys sharp, central vision. , "The data indicate ...
Cached Medicine News:Health News:US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 3Health News:Aegis Health Group Hires Pearson Talbert as Chief Development Officer 2Health News:drugstore.com Continues Global Sales Expansion to More Than 3.5 Billion International Consumers 2Health News:Sperm Gene May Cause Men's Longevity Disadvantage 2Health News:In Women, Aspirin Might Ward Off Eye Trouble 2
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Cystic Fibrosis Society Conference, MONMOUTH JUNCTION, N.J., ... from a Phase II clinical trial on its ... is being developed for the treatment of cystic ... the bacterium Pseudomonas,aeruginosa. The Phase II data indicated ...
... Conn., June 13 VION,PHARMACEUTICALS, INC. (Nasdaq: ... conducted Phase II trial of its lead anticancer ... (AML) and high-risk myelodysplastic syndromes (MDS) had been,presented ... Association (EHA),at the Bella Center in Copenhagen, Denmark. ...
Cached Medicine Technology:Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 2Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 3Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 4Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 5Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting 2Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting 3Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting 4
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Abrupt taper 2 mm from the end, then more gradual taper so that quick dilation of the punctum is obtained. Stainless steel. Round knurled with polished finish. Overall length: 5.5 inches....
Double ended dilator probes with gentle curve. Stainless steel. Round knurled handle with polished finish. Overall length: 5.3 inches....
Medicine Products: